Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 557

1.

Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma.

Schneeweiss S, Doherty M, Zhu S, Funch D, Schlienger RG, Fernandez-Vidaurre C, Seeger JD.

Dermatology. 2009;219(1):7-21. doi: 10.1159/000209289. Epub 2009 Mar 17.

PMID:
19293564
[PubMed - indexed for MEDLINE]
2.

Association between exposure to topical tacrolimus or pimecrolimus and cancers.

Hui RL, Lide W, Chan J, Schottinger J, Yoshinaga M, Millares M.

Ann Pharmacother. 2009 Dec;43(12):1956-63. doi: 10.1345/aph.1M278. Epub 2009 Nov 10.

PMID:
19903860
[PubMed - indexed for MEDLINE]
3.

Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis.

Arellano FM, Wentworth CE, Arana A, Fernández C, Paul CF.

J Invest Dermatol. 2007 Apr;127(4):808-16. Epub 2006 Nov 9.

PMID:
17096020
[PubMed - indexed for MEDLINE]
Free Article
4.

Administrative claims analysis of utilization and costs of care in health plan members with atopic dermatitis who had prior use of a topical corticosteroid and who initiate therapy with pimecrolimus or tacrolimus.

Delea TE, Gokhale M, Makin C, Hussein MA, Vanderpoel J, Sandman T, Chang J, Sung J, Pinkston P, Gause D, Jackson M.

J Manag Care Pharm. 2007 May;13(4):349-59.

PMID:
17506601
[PubMed - indexed for MEDLINE]
Free Article
5.

Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis.

Breuer K, Werfel T, Kapp A.

Am J Clin Dermatol. 2005;6(2):65-77. Review.

PMID:
15799678
[PubMed - indexed for MEDLINE]
6.

Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis.

Nghiem P, Pearson G, Langley RG.

J Am Acad Dermatol. 2002 Feb;46(2):228-41. Review.

PMID:
11807435
[PubMed - indexed for MEDLINE]
7.

[The treatment of atopic dermatitis in adults with topical calcineurin inhibitors].

Meurer M, Wozel G.

Hautarzt. 2003 May;54(5):424-31. Epub 2003 Apr 4. German.

PMID:
12719862
[PubMed - indexed for MEDLINE]
8.

Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies.

Thaçi D, Salgo R.

Clin Dermatol. 2010 Jan-Feb;28(1):52-6. doi: 10.1016/j.clindermatol.2009.04.001. Review.

PMID:
20082951
[PubMed - indexed for MEDLINE]
9.

[Long term management of childhood atopic dermatitis with calcineurin inhibitors].

Thaçi D.

Hautarzt. 2003 May;54(5):418-23. Epub 2003 Apr 4. German.

PMID:
12719861
[PubMed - indexed for MEDLINE]
10.

Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis.

Frankel HC, Qureshi AA.

Am J Clin Dermatol. 2012 Apr 1;13(2):113-23. doi: 10.2165/11597780-000000000-00000. Review.

PMID:
22263704
[PubMed - indexed for MEDLINE]
11.

The role of topical calcineurin inhibitors in atopic dermatitis.

Alomar A, Berth-Jones J, Bos JD, Giannetti A, Reitamo S, Ruzicka T, Stalder JF, Thestrup-Pedersen K; European Working Group on Atopic Dermatitis.

Br J Dermatol. 2004 Dec;151 Suppl 70 Dec 2004:3-27. Review.

PMID:
15548171
[PubMed - indexed for MEDLINE]
12.

An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance.

Langley RG, Luger TA, Cork MJ, Schneider D, Paul C.

Dermatology. 2007;215 Suppl 1:27-44. doi: 10.1159/000102118. Epub 2007 Dec 18. Review.

PMID:
18174691
[PubMed - indexed for MEDLINE]
13.

Pimecrolimus: new preparation. Me-too: too many risks, not beneficial enough in atopic dermatitis.

[No authors listed]

Prescrire Int. 2004 Dec;13(74):209-12.

PMID:
15599989
[PubMed - indexed for MEDLINE]
14.

Impact of topical calcineurin inhibitors on quality of life in patients with atopic dermatitis.

Ingram JR, Martin JA, Finlay AY.

Am J Clin Dermatol. 2009;10(4):229-37. doi: 10.2165/00128071-200910040-00003. Review.

PMID:
19489656
[PubMed - indexed for MEDLINE]
15.

Topical pimecrolimus: a review of its use in the management of pediatric atopic dermatitis.

Yang LP, Curran MP.

Paediatr Drugs. 2009;11(6):407-26. doi: 10.2165/10481960-000000000-00000. Review.

PMID:
19877726
[PubMed - indexed for MEDLINE]
16.

Meta-analysis on the comparison between two topical calcineurin inhibitors in atopic dermatitis.

Yin ZQ, Zhang WM, Song GX, Luo D.

J Dermatol. 2012 Jun;39(6):520-6. doi: 10.1111/j.1346-8138.2012.01529.x. Epub 2012 Mar 13. Retraction in: J Dermatol. 2013 May;40(5):418.

PMID:
22409418
[PubMed - indexed for MEDLINE]
17.

Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom.

Arellano FM, Arana A, Wentworth CE, Fernández-Vidaurre C, Schlienger RG, Conde E.

J Allergy Clin Immunol. 2009 May;123(5):1111-6, 116.e1-13. doi: 10.1016/j.jaci.2009.02.028. Epub 2009 Apr 10.

PMID:
19361841
[PubMed - indexed for MEDLINE]
18.

Calcineurin inhibitors in pediatric atopic dermatitis: a review of current evidence.

Kalavala M, Dohil MA.

Am J Clin Dermatol. 2011 Feb 1;12(1):15-24. doi: 10.2165/11319300-000000000-00000. Review.

PMID:
21067248
[PubMed - indexed for MEDLINE]
19.

The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update.

Thaçi D, Salgo R.

Acta Dermatovenerol Alp Pannonica Adriat. 2007 Jun;16(2):58, 60-62. Review.

PMID:
17992459
[PubMed - indexed for MEDLINE]
Free Article
20.

[Topical pimecrolimus and tacrolimus and the risk of cancer].

Sánchez-Pérez J.

Actas Dermosifiliogr. 2007 Jun;98(5):312-7. Review. Spanish.

PMID:
17555673
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk